Premium
Platinum Intercalators of DNA as Anticancer Agents
Author(s) -
Pages Benjamin J.,
GarbutcheonSingh K. Benjamin,
AldrichWright Janice R.
Publication year - 2017
Publication title -
european journal of inorganic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 1434-1948
DOI - 10.1002/ejic.201601204
Subject(s) - chemistry , cisplatin , carboplatin , cytotoxicity , intercalation (chemistry) , oxaliplatin , dna , ligand (biochemistry) , nucleobase , combinatorial chemistry , moiety , stereochemistry , platinum , in vitro , in vivo , biochemistry , organic chemistry , chemotherapy , receptor , cancer , medicine , catalysis , surgery , colorectal cancer , microbiology and biotechnology , biology
The drawbacks of the platinum chemotherapy agents cisplatin, carboplatin and oxaliplatin have inspired the development of compounds with different mechanisms of action. Polyaromatic platinum complexes (PPCs) are a promising anticancer alternative; these bind reversibly with DNA through the insertion of a planar aromatic moiety between nucleobases in a process known as intercalation. PPCs have demonstrated in vitro behaviour remarkably different from that of cisplatin and exhibited cytotoxicity up to one hundred times higher than that of cisplatin in many cell lines. This microreview primarily discusses 1,10‐phenanthroline‐based complexes of the type [Pt(P L )(A L )] 2+ (where P L is a polyaromatic ligand and A L is an ancillary ligand), including their cytotoxicity, DNA‐binding behaviour and biological activity in vitro and in vivo. Other PPCs within the field, including dual‐mode DNA binders incorporating tethered acridines and other potently cytotoxic complexes, are also covered.